
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is a promising biotechnology company with a strong pipeline of innovative allogeneic gamma delta T cell therapies. With multiple upcoming catalysts, including a clinical data update for their CD20-targeted CAR-T therapy in 1H26 and FDA alignment on a pivotal trial design in 2Q26, the company is positioned for potential value inflection points. In addition, Adicet's financial results were better than expected and they have a strong cash position to support operations into 2H27. Their lead product candidate, prulacabtagene leucel, has shown promising efficacy and a benign safety profile in lupus patients, setting it apart from competitors and potentially positioning it for success in a competitive autoimmune landscape. With risk-adjusted revenues for prula-cel already factored in, any additional indications could drive further upside for the company.
Bears say
Adicet Bio is facing an uncertain outlook due to their clinical product pipeline being in mid to late stage development, with no products currently on the market, and only two of their product candidates being studied in Phase 1 trials. Additionally, while they have a strong cash position currently, their high spending on research and development and general administrative expenses may jeopardize their financials in the long run. Due to these factors, the stock's reaction has been lackluster.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares